Strides Shasun (Q4 FY16): Strong end to FY16 – BUY
|
||
Indraprastha Gas (Q4 FY16): Weak quarter but robust outlook – BUY
|
||
Glenmark Pharmaceuticals (Q4 FY16): Sequential growth revival – BUY
Expect rerating to continue as Zetia launch looms; retain BUY and raise 1-year target to ₹1,100, based on 20x FY18E EPS |
||
Magma Fincorp Ltd. (Q4 FY16): Stress peaking out – BUY
Profitability to improve sharply over FY16-18, Maintain BUY |
||
Leave a Reply